vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Maison Solutions Inc. (MSS). Click either name above to swap in a different company.
Maison Solutions Inc. is the larger business by last-quarter revenue ($27.6M vs $18.7M, roughly 1.5× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -18.0%, a 17.2% gap on every dollar of revenue. On growth, Maison Solutions Inc. posted the faster year-over-year revenue change (-10.9% vs -25.7%). Over the past eight quarters, Maison Solutions Inc.'s revenue compounded faster (42.5% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Maison Solutions Inc.MSSEarnings & Financial Report
Maison Solutions Inc. is a specialty home goods retail company that provides a diverse portfolio of stylish, affordably priced furniture, home decor items, and daily household products. Its primary market is the Guangdong-Hong Kong-Macao Greater Bay Area in China, serving mass consumers through both offline physical stores and online e-commerce channels.
CTMX vs MSS — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $27.6M |
| Net Profit | $-154.0K | $-5.0M |
| Gross Margin | — | 23.4% |
| Operating Margin | -6.9% | -4.9% |
| Net Margin | -0.8% | -18.0% |
| Revenue YoY | -25.7% | -10.9% |
| Net Profit YoY | 97.6% | -1840.5% |
| EPS (diluted) | — | $-0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $27.6M | ||
| Q3 25 | — | $27.2M | ||
| Q2 25 | $18.7M | $34.4M | ||
| Q1 25 | $50.9M | $32.3M | ||
| Q4 24 | $38.1M | $29.4M | ||
| Q3 24 | $33.4M | $28.2M | ||
| Q2 24 | $25.1M | $16.9M | ||
| Q1 24 | $41.5M | $13.6M |
| Q4 25 | — | $-5.0M | ||
| Q3 25 | — | $-1.5M | ||
| Q2 25 | $-154.0K | $-287.4K | ||
| Q1 25 | $23.5M | $1.0M | ||
| Q4 24 | $18.9M | $-256.0K | ||
| Q3 24 | $5.7M | $700.9K | ||
| Q2 24 | $-6.5M | $-2.8M | ||
| Q1 24 | $13.8M | $-549.0K |
| Q4 25 | — | 23.4% | ||
| Q3 25 | — | 24.1% | ||
| Q2 25 | — | 9.5% | ||
| Q1 25 | — | 21.8% | ||
| Q4 24 | — | 26.9% | ||
| Q3 24 | — | 28.9% | ||
| Q2 24 | — | 13.0% | ||
| Q1 24 | — | 23.4% |
| Q4 25 | — | -4.9% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | -6.9% | -15.9% | ||
| Q1 25 | 44.4% | 3.7% | ||
| Q4 24 | 46.4% | 3.2% | ||
| Q3 24 | 12.3% | 7.3% | ||
| Q2 24 | -33.7% | -14.4% | ||
| Q1 24 | 28.1% | -2.3% |
| Q4 25 | — | -18.0% | ||
| Q3 25 | — | -5.7% | ||
| Q2 25 | -0.8% | -0.8% | ||
| Q1 25 | 46.2% | 3.1% | ||
| Q4 24 | 49.6% | -0.9% | ||
| Q3 24 | 17.2% | 2.5% | ||
| Q2 24 | -26.0% | -16.4% | ||
| Q1 24 | 33.3% | -4.0% |
| Q4 25 | — | $-0.23 | ||
| Q3 25 | — | $-0.08 | ||
| Q2 25 | — | $-0.02 | ||
| Q1 25 | — | $0.06 | ||
| Q4 24 | — | $-0.01 | ||
| Q3 24 | — | $0.04 | ||
| Q2 24 | — | $-0.16 | ||
| Q1 24 | — | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | — |
| Total DebtLower is stronger | — | $2.6M |
| Stockholders' EquityBook value | $119.9M | $11.6M |
| Total Assets | $175.1M | $75.4M |
| Debt / EquityLower = less leverage | — | 0.22× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | $49.0M | $775.4K | ||
| Q1 25 | $47.6M | $445.4K | ||
| Q4 24 | $38.1M | $355.7K | ||
| Q3 24 | $40.6M | $588.9K | ||
| Q2 24 | $43.2M | $2.1M | ||
| Q1 24 | $36.2M | $9.4M |
| Q4 25 | — | $2.6M | ||
| Q3 25 | — | $2.6M | ||
| Q2 25 | — | $2.6M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $2.5M | ||
| Q2 24 | — | $2.6M | ||
| Q1 24 | — | $2.6M |
| Q4 25 | — | $11.6M | ||
| Q3 25 | — | $10.1M | ||
| Q2 25 | $119.9M | $11.7M | ||
| Q1 25 | $25.0M | $12.0M | ||
| Q4 24 | $-456.0K | $10.9M | ||
| Q3 24 | $-23.5M | $11.2M | ||
| Q2 24 | $-31.2M | $10.5M | ||
| Q1 24 | $-31.7M | $13.3M |
| Q4 25 | — | $75.4M | ||
| Q3 25 | — | $73.3M | ||
| Q2 25 | $175.1M | $77.4M | ||
| Q1 25 | $98.5M | $82.7M | ||
| Q4 24 | $120.5M | $82.7M | ||
| Q3 24 | $139.0M | $82.1M | ||
| Q2 24 | $159.2M | $82.4M | ||
| Q1 24 | $184.7M | $44.2M |
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | 0.22× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.24× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-1.7M |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-1.7M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | $-15.8M | $-1.6M | ||
| Q1 25 | $-21.0M | $1.7M | ||
| Q4 24 | $-19.9M | $1.1M | ||
| Q3 24 | $-20.7M | $3.6M | ||
| Q2 24 | $-19.5M | $-2.6M | ||
| Q1 24 | $-26.0M | $-1.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | 1.66× | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | 5.12× | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
MSS
| Perishables | $14.4M | 52% |
| Nonperishables | $13.2M | 48% |
